Please use this identifier to cite or link to this item:
Title: Inhibition of PAK1 suppresses pancreatic cancer by stimulation of anti-tumour immunity through down-regulation of PD-L1.
Austin Authors: Wang, Kai;Zhan, Yifan;Huynh, Nhi;Dumesny, Chelsea;Wang, Xiao;Asadi, Khashayer;Herrmann, David;Timpson, Paul;Yang, Yang;Walsh, Katrina;Baldwin, Graham S;Nikfarjam, Mehrdad ;He, Hong 
Affiliation: St. Vincent's Clinical School, Faculty of Medicine, University of New South Wales, Sydney, New South Wales 2010, Australia
Department of Medical Biology, University of Melbourne, Parkville, 3050, Victoria, Australia
Invasion & Metastasis Group, Cancer Research Program, The Kinghorn Cancer Centre, Garvan Institute of Medical Research, Darlinghurst, NSW, Australia
Department of Surgery, Austin Health, The University of Melbourne, Heidelberg, Victoria, Australia
Department of Anatomical Pathology, Austin Health, Heidelberg, Victoria, Australia
Immunology Division, The Walter and Eliza Hall Institute for Medical Research, Parkville, Victoria, Australia
Issue Date: 1-Mar-2020
Date: 2019-12-16
Publication information: Cancer letters 2019; 472: 8-18
Abstract: Immunotherapies have not yielded significant clinical benefits for pancreatic ductal adenocarcinoma (PDA) because of the existence of an immunosuppressive tumour microenvironment (TME) characterized by a desmoplastic stroma containing infiltrated immune cells and activated pancreatic stellate cells (PSCs). This study aims to investigate the involvement of PAK1 in anti-tumour immunity. In PDA patients, low PAK1 expression, low activation of PSC and high CD8+ T cell/PAK1 ratios correlated with longer overall survival. In a murine PDA model, PAK1 knockout increased intra-tumoral CD4+ and CD8+ T cells, inhibited PSCs activation and extended survival. Inhibition of PAK1 reduced PSC-stimulated PDA cell proliferation and migration, blocked PSC-mediated protection of PDA cells from killing by cytotoxic lymphocytes and decreased intrinsic and PSC-stimulated PD-L1 expression in PDA cells, which further sensitized PDA cells to cytotoxic lymphocytes. Inhibition of PAK1 stimulates anti-tumour immunity by increasing intra-tumoral CD4+ and CD8+ T cells, and by sensitizing PDA cells to killing by cytotoxic lymphocytes via down-regulation of intrinsic and PSC-stimulated PD-L1 expression. PAK1 inhibitors, especially in combination with immune checkpoint inhibitors may result in improved efficacy of immunotherapy of PDA.
DOI: 10.1016/j.canlet.2019.12.020
ORCID: 0000-0003-4866-276X
Journal: Cancer letters
PubMed URL: 31857154
Type: Journal Article
Subjects: Pancreatic stellate cells
Programmed death-ligand 1
Tumour microenvironment
p21-activated kinase 1
Appears in Collections:Journal articles

Show full item record

Page view(s)

checked on Apr 13, 2024

Google ScholarTM


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.